US 3794726A
· Ariyan
· 1974
[cited by applicant]
US 4959367A
· King
· 1990
[cited by applicant]
US 7253164B2
· Molteni et al.
· 2007
[cited by applicant]
US 8642660B2
· Goldfarb
· 2014
[cited by applicant]
US 9556130B2
· Hitchcock et al.
· 2017
[cited by applicant]
US 9770450B2
· Hitchcock et al.
· 2017
[cited by applicant]
US 20060079696A1
· Masson et al.
· 2006
[cited by applicant]
US 20230310441A1
· Arkilo et al.
· 2023
[cited by applicant]
JP 2011507910A
· 2011
[cited by applicant]
WO WO2004022521A1
· 2004
[cited by applicant]
WO WO2004108673A2
· 2004
[cited by applicant]
WO WO2007073303A2
· 2007
[cited by applicant]
WO WO2008018827A2
· 2008
[cited by applicant]
WO WO2011138265A2
· 2011
[cited by applicant]
WO WO2014152917A2
· 2014
[cited by applicant]
WO WO2016081736A1
· 2016
[cited by applicant]
WO WO2021224680A2
· 2021
[cited by applicant]
WO WO2022058791A1
· 2022
[cited by applicant]
Burk, M. J. et al., “A Convenient Asymmetric Synthesis of Alpha-1-Arylalkylamines Through the Enantioselective Hydrogenation of Enamides,” Journal of the American Chemical Society, American Chemical Society, US, vol. 11…
[cited by applicant]
Schmidt, J. et al., “Mass spectroscopy of natural products. 20-Quinazoline carboxylic acids 4-Comparative positive and negative ion mass spectroscopic studies of 3,4-dihydroquinazolin-4-on-3-ylalkanoic acids and 3,4-dih…
[cited by applicant]
Vaisburg, A. et al., “(2-Amino-phenyl)-amides of -omega—substituted alkanoic acids as new histone deacetylase inhibitors,” Bioorganic & Medicinal Chemistry Letters, Elsevier, Amsterdam, NL, vol. 14, No. 1, Jan. 5, 2004,…
[cited by applicant]
Abi-Dargham et al., “Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort” American Journal of Psychiatry, 155(6), 761-767 (1998).
[cited by applicant]
Atienza et al., “S39. GPR139 An Ophan GPCR Affecting Negative Domains Of Schizophrenia,” Abstracts for the Sixth Biennial SIRS Conference, Poster Session III, S339.
[cited by applicant]
Bean et al., “Hybrid Concept Elicitation and Cognitive Debriefing Patient Interviews to Establish Content Validity of the Dimensional Anhedonia Rating Scale (DARS)”, Poster, American College of Neuropsychopharmacology (…
[cited by applicant]
Berge, S. M., Bighley, L. D., & Monkhouse, D. C., “Pharmaceutical Salts,”
[cited by applicant]
Bianco et al. “The habenular nuclei: a conserved asymmetric relay station in the vertebrate brain” Phil. Trans. R. Soc. B, 364, pp. 1005-1020 (2009).
[cited by applicant]
Boraei et al., “Design and Synthesis of New Phthalazin-Based Derivatives as Potential EGFR Inhibitors for the Treatment of Hepatocellular Carcinoma”, Bioorganic Chemistry, vol. 85, pp. 293-307 (2019).
[cited by applicant]
Breier et al., “Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method,” Proceedings of the National Academy of Sciences…
[cited by applicant]
Brown et al., Labelling of the D
[cited by applicant]
Burk, et al., “A Convenient Asymmetric Synthesis of α-1-Arylalkylamines through the Enantioselective Hydrogenation of Enamides,”
[cited by applicant]
Castellani, et al., “Copy Number Variation Distribution in Six Monozygotic Twin Pairs Discordant for Schizophrenia,”
[cited by applicant]
Castellani et al., “Biological relevance of CNV calling methods using familial relatedness including monozygotic twins” BMC Bioinformatics 15, 114 (2014).
[cited by applicant]
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, pp. 1004-1010, 1996.
[cited by applicant]
Chianetta et al., “Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder,” Schizophrenia Research 105, pp. 86-94 (2008).
[cited by applicant]
Christoph et al., “Stimulation of the lateral habenula inhibits dopamine-containing neurons in the substantia nigra and ventral tegmental area of the rat,” The Journal of Neuroscience, 6(3), pp. 613-619 (1986).
[cited by applicant]
Cilibrizzi et al., “6-Methyl-2,4-Disubstituted Pyridazin-3-ones: A Novel Class of Small-Molecule Agonists for Formyl Peptide Receptors,” Journal of Medicinal Chemistry, vol. 52, pp. 5044-5057 (2009).
[cited by applicant]
Coyle, “Schizophrenia: Basic and Clinical” Advances in Neurobiology, 2017, 15, pp. 255-280.
[cited by applicant]
Dai et al., “Abnormal Regional Cerebral Blood Flow in Cognitively Normal Elderly Subjects With Hypertension” Stroke, 39, pp. 349-354 (2008).
[cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Aug. 24, 2008, XP002754167, retrieved from STN; Database accession No. 1043204-06-3 (eight pages).
[cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Mar. 26, 2014, XP002754168, retrieved from STN; Database accession No. 1574302-61-6 (eighteen pages).
[cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Aug. 4, 2010, XP002754169, retrieved from STN; Database accession No. 1234906-37-6 (eighteen pages).
[cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; XP002754170 (four pages).
[cited by applicant]
Dermer et al., “Another Anniversary for the War on Cancer.” Nat Biotechnol., 12, p. 320 (1994).
[cited by applicant]
Dewey et al., “Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels” Synapse, 13, pp. 350-356 (1993).
[cited by applicant]
Dewey et al., “Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects,” Proc. Nat. Aca. Sci., 90 (24), pp. 11816-11820 (1993).
[cited by applicant]
Dewey et al. “Modulation of Central Cholinergic Activity by GABA and Serotonin: PET Studies with
[cited by applicant]
Diethelm, et al., “Amine-Selective Bioconjugation Using Arene Diazonium Salts”, Organic Letters, 16, pp. 3908-3911 (2014).
[cited by applicant]
Dvorak, et al. “Identification and SAR of glycine benzamides as potent agonists for the GPR139 receptor”, ACS Medicinal Chemistry Letters, vol. 6, pp. 1015-1018 (2015).
[cited by applicant]
Freshney et al., “Culture of Animal Cells, A Manual of Basic Technique” 1983 (seven pages).
[cited by applicant]
Fusar-Poli et al., “Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials,” Schizophrenia Bulletin, vol. pp. 892-899 (2015).
[cited by applicant]
Ginovart et al. “Binding characteristics and sensitivity to endogenous dopamine of [
[cited by applicant]
Ginovart et al., “Positron Emission Tomography Quantification of [
[cited by applicant]
Grabner et al., “Symmetric Atlasing and Model Based Segmentation: An Application to the Hippocampus in Older Adults” In Medical Image Computing and Computer-Assisted Intervention, pp. 58-66, (2006).
[cited by applicant]
Graff-Guerrero et al., “Blockade of [
[cited by applicant]
Gunn et al., “Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model,” Neurolmage, vol. 6 pp. 279-287 (1997).
[cited by applicant]
Gunn et al., “Molecular Imaging And Kinetic Analysis Toolbox (MIAKAT)—A Quantitative Software Package for the Analysis of PET Neuroimaging Data”, Journal of Nuclear Medicine, 57 (2016) (five pages).
[cited by applicant]
Hawkins et al., “An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers,” Hum. Brain Mapp, vol. 39, pp. 319-331 (2018).
[cited by applicant]
Hitchcock, Stephen A, “Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds”, Journal of Medicinal Chemistry, 2012, vol. 55, pp. 4877-4895.
[cited by applicant]
Hodgson et al., “Discovery of TAK-041: Potent and Selective GPR139 Agonist for the Treatment of Negative Symptoms Associated with Schizophrenia”, Poster, Society for Neuroscience, 2019.
[cited by applicant]
Hunter et al., “Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment,” European Psychiatry, 27(6), pp. 432-436 (2012).
[cited by applicant]
Innis,. :Neuroreceptor imaging with Spect.
[cited by applicant]
Innis et al., “Amphetamine-stimulated dopamine release competes in vivo for [
[cited by applicant]
Isberg, et al., “Computer-Aided Discovery of Aromatic L-α-Amino Acids as Agonists of the Orphan G Protein-Coupled Receptor GPR139”,
[cited by applicant]
Jenkinson et al., “BET2—MR-Based Estimation of Brain, Skull and Scalp Surfaces”, Eleventh Annual Meeting of the Organization for Human Brain Mapping, 2005.
[cited by applicant]
Jhou et al., “The mesopontine rostromedial tegmental nucleus: A structure targeted by the lateral habenula that projects to the ventral tegmental area of Tsai and substantia nigra compacta,” J. Comp. Neurol., 513, pp. 5…
[cited by applicant]
Jhou et al., “The Rostromedial Tegmental Nucleus (RMTg), a GABAergic Afferent to Midbrain Dopamine Neurons, Encodes Aversive Stimuli and Inhibits Motor Responses,” Neuron, 61, pp. 786-800 (2009).
[cited by applicant]
Juckel et al., “Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics”
[cited by applicant]
Juckel et al., “Ventral Striatal Activation During Expectancy Of Reward In Patients With ultra-High Risk For Schizophrenia,” Schizophrenia Research, 86, p. S10 (2006).
[cited by applicant]
Juckel et al., “Dysfunction of ventral striatal reward prediction in schizophrenia,”
[cited by applicant]
Kamel et al., “In Vitro Metabolism of Slowly Cleared G Protein-Coupled Receptor 139 Agonist TAK-041 Using Rat, Dog, Monkey, and Human Hepatocyte Models (HepatoPac): Correlation with In Vivo Metabolism,”
[cited by applicant]
Keefe et al., “The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery”
[cited by applicant]
Lally et al., “Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses,”
[cited by applicant]
Lammertsma et al., “Simplified Reference Tissue Model for PET Receptor Studies,”
[cited by applicant]
Laruelle et al., “SPECT Imaging of Striatal Dopamine Release after Amphetamine Challenge”
[cited by applicant]
Laruelle et al., “Imaging D
[cited by applicant]
Laruelle et al., “Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates”
[cited by applicant]
Laruelle et al., “Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [
[cited by applicant]
Laruelle, “The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies,”
[cited by applicant]
Laruelle, “Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review,”
[cited by applicant]
Li et al., “Role of the Lateral Habenula in Pain-Associated Depression”,
[cited by applicant]
Liu et al., “GPR139, an Orphan Receptor Highly Enriched in the Habenula and Septum, Is Activated by the Essential Amino Acids I-Tryptophan and I-Phenylalanine,” Molecular Pharmacology, vol. 88, pp. 911-925 (2015).
[cited by applicant]
McGrath et al., “Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality”
[cited by applicant]
Narendran et al., “In vivo vulnerability to competition by endogenous dopamine: Comparison of the D
[cited by applicant]
Nielsen et al., “Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients,”
[cited by applicant]
Nielsen et al., “δ-Opioid Receptor Function in the Dorsal Striatum Plays a Role in High Levels of Ethanol Consumption in Rats,”
[cited by applicant]
Nøhr et al., “The GPR139 reference agonists 1a and 7c, and tryptophan and phenylalanine share a common binding site,”
[cited by applicant]
Okuzumi, et al., “Efficient solid-phase synthesis of diverse 1,2,3-benzotriazin-4-ones using tert-butyl nitrite,”
[cited by applicant]
Owen et al., “Schizophrenia,”
[cited by applicant]
Rabiner et al., “Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [
[cited by applicant]
Radua et al., “Ventral Striatal Activation During Reward Processing in Psychosis,”
[cited by applicant]
Reichard, et al., “Discovery of TAK-031: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia,”
[cited by applicant]
Sahu et al., “Cognitive Impairment in Schizophrenia: Interplay of BDNF and Childhood Trauma? A Review of Literature,”
[cited by applicant]
Sakurai et al., “Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data,”
[cited by applicant]
Schiffer, et al., “The Selective GPR139 Agonist TAK-041 Reverses Anhedonia and Social Interaction Deficits in Rodent Models Related to Negative Symptoms in Schizophrenia,” SIRS 2020 Abstracts, pp. S106-S107.
[cited by applicant]
Schiffer, et al., “The Selective GPR139 Agonist TAK-041 Reverses Anhedonia and Social Interaction Deficits in Rodent Models Related to Negative Symptoms in Schizophrenia,” poster presentation (one page).
[cited by applicant]
Schmidt, et al., “Mass spectroscopy of natural products. 20-Quinazoline carboxylic acids 4-Comparative positive and negative ion mass spectroscopic studies of 3,4-dihydroquinazolin-4-on-3-ylalkanoic acids and 3,4-dihydr…
[cited by applicant]
Searle et al., “PET imaging of dopamine Da receptors in humans with [
[cited by applicant]
Searle et al., “PET imaging of dopamine D
[cited by applicant]
Searle et al., “Imaging Dopamine D
[cited by applicant]
Sego et al., “Lateral habenula and the rostromedial tegmental nucleus innervate neurochemically distinct subdivisions of the dorsal raphe nucleus in the rat,”
[cited by applicant]
Shi, et al., “Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139,” ACS Medicinal Chemistry Letters, vol. 2, pp. 303-306 (2011).
[cited by applicant]
Shotbolt et al., “Within-Subject Comparison of [
[cited by applicant]
Smith et al., “Advances in functional and structural MR image analysis and implementation as FSL,”
[cited by applicant]
Strauss et al. “A New Perspective on Anhedonia in Schizophrenia,”
[cited by applicant]
Tedroff et al., “Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET,”
[cited by applicant]
Tedroff et al., “Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration,”
[cited by applicant]
Treadway et al. “Reconsidering Anhedonia in Depression: Lessons from Translational Neuroscience,”
[cited by applicant]
Tziortzi et al., “Imaging dopamine receptors in humans with [
[cited by applicant]
Tziortzi et al., “MR-DTI and PET multimodal imaging of dopamine release within subdivisions of basal ganglia,” Journal of Physics: Conference Series, vol. 317, (2011) (three pages).
[cited by applicant]
Tziortzi et al., “A diffusion tensor imaging (DTI) and [11C]PHNO PET study to measure dopamine release in the functional subdivisions of the basal ganglia,” Journal of Nuclear Medicine, 52 (2011) (four pages).
[cited by applicant]
Vaisburg, et al., “(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors,”
[cited by applicant]
Vedel et al., “Pharmacology and function of the orphan GPR139 G protein-coupled receptor,” vol. 126, Issue S6, pp. 35-46 (2019).
[cited by applicant]
Verhoeff et al., “Radiotracer imaging of dopamine transporters and presynaptic dopamine synthesis in parkinsonian syndromes,”
[cited by applicant]
Verhoeff et al., “A Simple Method to Measure Baseline Occupancy of Neostriatal Dopamine D
[cited by applicant]
Verhoeff et al., “Imaging of dopaminergic transmission in neuropsychiatric disorders,”
[cited by applicant]
Verhoeff et al., “The Role of Neuroimaging in Development of and Treatment With Antipsychotics,”
[cited by applicant]
Verhoeff et al., “Dopamine depletion results in increased neostriatal D
[cited by applicant]
Wang et al., “Opiate-associated contextual memory formation and retrieval are differentially modulated by dopamine D1 and D2 signaling in hippocampal-prefrontal connectivity,”
[cited by applicant]
Willeit et al., “High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [
[cited by applicant]
Willeit et al., “Effects of D-amphetamine on binding of the new D2/3 receptor agonist radioligand [11C]-(+)-PHNO in humans,”
[cited by applicant]
Wilson et al., “Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with P…
[cited by applicant]
Yin et al., “A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia,”
[cited by applicant]
Zhu et al., “Altered Coupling Between Resting-State Cerebral Blood Flow and Functional Connectivity in Schizophrenia,”
[cited by applicant]
“A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizo…
[cited by applicant]
“Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study,” clinicaltrials.gov (19 pages).
[cited by applicant]
U.S. Appl. No. 17/450,677, filed Oct. 12, 2021.
[cited by applicant]
U.S. Appl. No. 17/725,663, filed Apr. 21, 2022.
[cited by applicant]
U.S. Appl. No. 18/050,781, filed Oct. 28, 2022.
[cited by applicant]
U.S. Appl. No. 18/328,235, filed Jun. 2, 2023.
[cited by applicant]